GLEEVEC (Imatinib) Product Description

GLEEVEC, known generically as Imatinib, is a targeted therapy medication used primarily to treat certain types of cancer, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It works by inhibiting specific proteins that promote cancer cell growth, effectively slowing or stopping the progression of the disease.

Indications

GLEEVEC is indicated for:

• Chronic myeloid leukemia (CML) in the chronic phase, accelerated phase, and blast crisis.
• Gastrointestinal stromal tumors (GISTs) that are unresectable or metastatic.
• Other conditions as determined by a healthcare provider.

Mechanism of Action

Imatinib specifically targets and inhibits the BCR-ABL tyrosine kinase, a protein produced by the Philadelphia chromosome abnormality found in CML. By blocking this enzyme, GLEEVEC disrupts the signaling pathways that promote cancer cell proliferation and survival.

Dosage and Administration

GLEEVEC is typically administered orally, with the dosage determined based on the type of cancer being treated. It is important to follow the prescribed dosage and schedule provided by your healthcare provider.

Possible Side Effects

Common side effects may include:

• Nausea and vomiting
• Diarrhea
• Fatigue
• Swelling or fluid retention
• Skin rashes

Serious side effects can occur and should be reported to a healthcare provider immediately.

Precautions

Before starting GLEEVEC, inform your healthcare provider about any existing medical conditions, allergies, or medications you are currently taking. Regular monitoring and follow-up are essential during treatment to assess effectiveness and manage side effects.

Conclusion

GLEEVEC (Imatinib) is a vital medication in the management of specific cancers. Its targeted action helps improve patient outcomes and quality of life. Always consult with a healthcare professional for personalized medical advice and treatment plans.